Munro Partners Acquires 14,730 Shares of Boston Scientific Corporation $BSX

Munro Partners raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,256,810 shares of the medical equipment provider’s stock after acquiring an additional 14,730 shares during the quarter. Boston Scientific makes up approximately 3.1% of Munro Partners’ holdings, making the stock its 13th biggest position. Munro Partners’ holdings in Boston Scientific were worth $119,837,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BSX. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Main Street Financial Solutions LLC boosted its holdings in shares of Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its holdings in shares of Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its holdings in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.5%

Shares of Boston Scientific stock opened at $46.69 on Tuesday. Boston Scientific Corporation has a 1 year low of $45.99 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $69.39 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 0.89 and a beta of 0.56. The business has a fifty day simple moving average of $56.05 and a two-hundred day simple moving average of $74.40.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter last year, the firm earned $0.75 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its board has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. BTIG Research reissued a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Tuesday. Jefferies Financial Group cut their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Leerink Partners cut their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Finally, Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $85.08.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.